论文部分内容阅读
目的评价氟罗沙星序贯疗法与静脉滴注疗法治疗泌尿系统感染的成本-效果。方法将86例泌尿系统感染患者随机分为氟罗沙星序贯组与静脉滴注组,各43例。2组患者初始均静脉滴注氟罗沙星,每日2次,每次0.2 g。3 d后,序贯组改为口服氟罗沙星片,每次0.2 g,每日2次,连用4～7 d;静脉滴注组则继续用药4～7 d。观察2组的疗效并进行成本-效果分析。结果氟罗沙星序贯组与静脉滴注组的治疗有效率分别为91%和93%,细菌学清除率分别为88%和91%,不良反应发生率均为5%,均无显著差异(P>0.05),而成本-效果比分别为369.24和941.94。结论氟罗沙星序贯疗法的成本-效果优于静脉滴注疗法。
Objective To evaluate the cost-effectiveness of sequential and intravenous drip therapy of fleroxacin in the treatment of urinary tract infections. Methods Totally 86 patients with urinary tract infection were randomly assigned to fleroxacin sequential group and intravenous drip group, with 43 cases in each group. Two groups of patients were initially infused fleroxacin intravenously, 2 times a day, each 0.2 g. After 3 days, the sequential group was changed to oral flossarone tablets 0.2 g once daily for 4 to 7 days. The intravenous drip group continued for 4 to 7 days. The efficacy of the two groups was observed and the cost-effectiveness analysis was performed. Results The effective rates of treatment with fleroxacin were 91% and 93%, respectively. The bacteriological clearance rates were 88% and 91% respectively, and the incidence of adverse reactions was 5% (P > 0.05), while the cost-effectiveness ratios were 369.24 and 941.94, respectively. Conclusions The cost-effectiveness of sequential floxuron therapy is superior to intravenous drip therapy.